IPO Year: 2024
Exchange: AMEX
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3/A - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
424B4 - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
EFFECT - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
S-1/A - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
8-A12B/A - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
S-1/A - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the closing of its previously announced initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares began trading on the NYSE American Market on September 16, 2024, under the ticker symbol "IBO". In addition, Impact has granted the underwriters a 45-day option to purchase up to an additional 225,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offere
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE:IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol "IBO," these shares will begin trading on the NYSE American Market on September 16, 2024. This significant achievement underscores Impact BioMedical's innovative contributions to the healthcare sector and represents a major milestone for DSS. We ar
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares are expected to begin trading on the NYSE American Market on September 16, 2024, under the ticker symbol "IBO." The offering is expected to close on September 17, 2024, subject to the satisfaction of customary closing conditions. In addition, Impact has granted the underwriters a 45-day option to purchase an additional 225,000 shares of its common stock at the public offeri